U.S. Alliance Pharma Acquires U.K.-based LGC’s Drug Development Solutions (DDS) Business

13 Jul 2022
www.biospace.com
Gene TherapySmall molecular drugAcquisitionCollaborate
Expands bioanalytical services to include many emerging areas worldwide MALVERN, Pa.--(BUSINESS WIRE)-- Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions (DDS), a U.K.-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a global healthcare private equity firm, and KKR & Co. Inc. (KKR) (NYSE:KKR), a leading global investment firm, are equal shareholders in the combined company. This transaction expands bioanalytical, analytical material testing and laboratory capabilities internationally for the biopharma and pharma industry, including areas of cell and gene therapy, next-generation biologics, material sciences and protein characterization. “Together, Alliance and DDS will partner with customers on a global basis to provide advanced bioanalytical and analytical material services for both large and small molecules, particularly supporting many emerging bioanalytical and analytical science areas the industry needs right now,” said Alliance Chairman of the Board and a Partner at Ampersand Capital Partners Dave Patteson. “Alongside Alliance’s bioanalytical expertise, DDS adds an unrivalled breadth and depth of expertise in bioanalysis and analytical and materials science as well as two state-of-the-art analytical labs in Cambridge (Fordham), U.K., and Sandwich, Kent, U.K. Their Cambridge facility is one of the largest bioanalytical centers in the world with about 270 employees.” This acquisition positions Alliance to become an international bioanalytical service provider for all therapeutic modalities. About Alliance Pharma Founded in 2008, Alliance is a contract research organization (CRO) in Malvern, PA, just outside of Philadelphia that specializes in advanced bioanalytical research services for both small and large molecule drugs, as well as drug metabolism studies to support pharmaceutical and biotechnology companies’ drug discovery and development programs. Alliance’s mission is to build a trusted partnership with our clients to support their successful drug development programs. Our business philosophy is based on a foundation of trust, professional ethics, scientific excellence and regulatory compliance. About Drug Development Solutions (An LGC Business Unit) DDS’s Bioanalytical solutions include liquid-chromatography mass spectrometry (LC-MS) and immunoassay bioanalysis, to provide data for pharmacokinetics, immunogenicity, pharmacodynamics and cell-based assays supporting all phases of drug development to GCP and GLP standards. Its Analytical Materials Sciences solutions provides specialist testing of raw materials, formulated products, packaging and medical devices for trace impurities, contamination, degradation and quality control to support CMC (Chemistry Manufacturing and Control) analytical testing to GMP (Good Manufacturing Practice) standard. About Ampersand Capital Partners Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at ampersandcapital.com. About KKR KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at and on Twitter @KKR_Co. View source version on businesswire.com: Contacts Lindsey Langemeier SCORR Marketing 402-405-4269 lindsey@scorrmarketing.com Source: Alliance Pharma View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.